BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31354356)

  • 21. Endocan as a prognostic biomarker of triple-negative breast cancer.
    Sagara A; Igarashi K; Otsuka M; Kodama A; Yamashita M; Sugiura R; Karasawa T; Arakawa K; Narita M; Kuzumaki N; Narita M; Kato Y
    Breast Cancer Res Treat; 2017 Jan; 161(2):269-278. PubMed ID: 27888420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer.
    Sheng J; Xue X; Jiang K
    Curr Mol Med; 2019; 19(2):147-155. PubMed ID: 30854965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proliferation, migration and invasion of triple negative breast cancer cells are suppressed by berbamine via the PI3K/Akt/MDM2/p53 and PI3K/Akt/mTOR signaling pathways.
    Liu L; Yan J; Cao Y; Yan Y; Shen X; Yu B; Tao L; Wang S
    Oncol Lett; 2021 Jan; 21(1):70. PubMed ID: 33365081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Novel IGLC2 Gene Linked With Prognosis of Triple-Negative Breast Cancer.
    Chang YT; Tsai WC; Lin WZ; Wu CC; Yu JC; Tseng VS; Liao GS; Hu JM; Hsu HM; Chang YJ; Lin MC; Chu CM; Yang CY
    Front Oncol; 2021; 11():759952. PubMed ID: 35155184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methionine adenosyltransferases in cancers: Mechanisms of dysregulation and implications for therapy.
    Maldonado LY; Arsene D; Mato JM; Lu SC
    Exp Biol Med (Maywood); 2018 Jan; 243(2):107-117. PubMed ID: 29141455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MELK as a potential target to control cell proliferation in triple-negative breast cancer MDA-MB-231 cells.
    Li G; Yang M; Zuo L; Wang MX
    Oncol Lett; 2018 Jun; 15(6):9934-9940. PubMed ID: 29805690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. UNBS5162 induces growth inhibition and apoptosis via inhibiting PI3K/AKT/mTOR pathway in triple negative breast cancer MDA-MB-231 cells.
    Yue X; Li M; Chen D; Xu Z; Sun S
    Exp Ther Med; 2018 Nov; 16(5):3921-3928. PubMed ID: 30344670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
    Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
    Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FOXO3a expression is associated with lymph node metastasis and poor disease-free survival in triple-negative breast cancer.
    Rehman A; Kim Y; Kim H; Sim J; Ahn H; Chung MS; Shin SJ; Jang K
    J Clin Pathol; 2018 Sep; 71(9):806-813. PubMed ID: 29588373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
    Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
    Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gomisin G Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing AKT Phosphorylation and Decreasing Cyclin D1.
    Maharjan S; Park BK; Lee SI; Lim Y; Lee K; Kwon HJ
    Biomol Ther (Seoul); 2018 May; 26(3):322-327. PubMed ID: 29587339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells.
    Cook MT; Liang Y; Besch-Williford C; Hyder SM
    Breast Cancer (Dove Med Press); 2017; 9():9-19. PubMed ID: 28096694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CPNE1 predicts poor prognosis and promotes tumorigenesis and radioresistance via the AKT singling pathway in triple-negative breast cancer.
    Shao Z; Ma X; Zhang Y; Sun Y; Lv W; He K; Xia R; Wang P; Gao X
    Mol Carcinog; 2020 May; 59(5):533-544. PubMed ID: 32181526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Knockdown of cell division cycle-associated protein 4 expression inhibits proliferation of triple negative breast cancer MDA-MB-231 cells
    Pang S; Xu Y; Chen J; Li G; Huang J; Wu X
    Oncol Lett; 2019 May; 17(5):4393-4400. PubMed ID: 30944632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells.
    Liu CY; Chu PY; Huang CT; Chen JL; Yang HP; Wang WL; Lau KY; Lee CH; Lan TY; Huang TT; Lin PH; Dai MS; Tseng LM
    Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30658422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. hMAGEA2 promotes progression of breast cancer by regulating Akt and Erk1/2 pathways.
    Park S; Sung Y; Jeong J; Choi M; Lee J; Kwon W; Jang S; Park SJ; Kim HS; Lee MH; Kim DJ; Liu K; Kim SH; Dong Z; Ryoo ZY; Kim MO
    Oncotarget; 2017 Jun; 8(23):37115-37127. PubMed ID: 28415749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting PVT1 Exon 9 Re-Expresses Claudin 4 Protein and Inhibits Migration by Claudin-Low Triple Negative Breast Cancer Cells.
    Levine F; Ogunwobi OO
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33801373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Knockdown of nucleophosmin 1 suppresses proliferation of triple-negative breast cancer cells through activating CDH1/Skp2/p27kip1 pathway.
    Zeng D; Xiao Y; Zhu J; Peng C; Liang W; Lin H
    Cancer Manag Res; 2019; 11():143-156. PubMed ID: 30613163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MiR-890 inhibits proliferation and invasion and induces apoptosis in triple-negative breast cancer cells by targeting CD147.
    Wang C; Xu C; Niu R; Hu G; Gu Z; Zhuang Z
    BMC Cancer; 2019 Jun; 19(1):577. PubMed ID: 31196010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.